fda ghk-cu injectable approval FDA restores non-injectable GHK-Cu to

This analysis verifies that the molecular weight of the synthesized peptide matches the theoretical mass of the BPC-157 sequence (1419.5 g/mol), ensuring that the correct compound has been produced

Publication and related biases

Alt Text: GHK-Cu peptide claim strength matrix comparing topical skin aging, wound-care context, hair growth, injectable regeneration, and systemic anti-aging evidence

Healthcare law firms analyzing the question conclude that a salt-form change does not create meaningful legal differentiation under the "essentially a copy" doctrine the same reasoning the FDA uses to prevent minor modifications from circumventing drug regulations